Ammonium metabolism rewiring in the prostate cancer microenvironment: Mechanisms and clinical prospects

Zihao Ye1, Hao Wu1, Zhanhao Li1

  • 1Department of Urology II, The First Hospital of Jilin University, Changchun, China.

Frontiers in Oncology
|November 3, 2025
PubMed

Insights

Ammonium metabolism fuels prostate cancer growth and reshapes the tumor microenvironment (TME). Targeting this pathway offers new therapeutic strategies and biomarkers for prostate cancer intervention.

Area of Science:

  • Oncology
  • Metabolic Reprogramming
  • Tumor Microenvironment (TME)

Background:

  • Ammonium metabolism is understudied in prostate cancer, unlike lipid metabolism and the Warburg effect.
  • The urea cycle's role in prostate cancer immune regulation is insufficiently explored.
  • Metabolic reprogramming links nutrient breakdown to biosynthesis, impacting tumor progression.

Purpose of the Study:

  • To explore the role of ammonium metabolism in prostate tumorigenesis and TME remodeling.
  • To investigate the link between ammonium metabolism and tumor immune regulation.
  • To propose novel therapeutic strategies and biomarkers for prostate cancer.

Main Methods:

  • Review of mechanistically validated insights from in vivo/in vitro models.
  • Analysis of clinical trials involving ammonium-targeting inhibitors.
  • Synthesis of data on oncogenic drivers (Myc, p53) modulating ammonium metabolism.

Main Results:

  • Ammonium metabolism reprogramming drives prostate tumorigenesis and TME immunosuppression via M2 macrophage polarization.
  • It mediates immune evasion through glutathione-dependent redox homeostasis disruption.
  • This pathway may trigger ferroptosis via the GSH/GPX4 axis, offering therapeutic potential.

Conclusions:

  • Ammonium metabolism is a critical driver of prostate cancer progression and immune evasion.
  • Targeting ammonium metabolism presents promising therapeutic avenues and biomarker candidates.
  • Further research into ammonium metabolism's impact on citrate and polyamine metabolism in prostate cancer is warranted.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K